Clinical implication of serum sIL-2R levels in ovarian cancer

Abstract

The levels of serum soluble interleukin-2 receptor (sIL-2R) of 36 patients with ovarian cancer, 34 with benign gynecological tumors and 31 blood donors were measured by ELISA. Compared to those of benign and normal controls, serum levels of sIL-2R in patients with ovarian cancer elevated significantly (P <0.01). Serum sIL-2R levels were likely related to types, clinical stage or histological grading of ovarian cancer. We were led to conclude that serum sIL-2R level may reflect the status of the immune system and the disease severity in patients with ovarian cancer. Its value as a marker for monitoring treatment and prognosis needs further studies.

Keywords

sIL-2R / ovarian cancer / serum

References

[1] VivianiS, CameriniE, BonfanteV, et al. . Soluble interleukin-2 receptors (sIL-2R) in Modgkin’s disease: outcome and clinical implications. Br J Cancer, 1998, 77(6): 992-992

[2] KobayashiS, ImamuraM, HashinoS, et al. . Clinical relevance of serum soluble interleukin-2 receptor levels in acute and chronic graft-versushost disease. Leuk Lymphoma, 1997, 28(1-2): 159-159

[3] RadkeJ, SchmidtD, BohmeM, et al. . Cytokine level in malignant ascites and peripheral blood of patients with advanced ovarian carcinoma. Geburtshilfe Frauenheilkd, 1996, 56(2): 83-83

[4] GadducciA, FerdeghiniM, MalagninoG, et al. . Elevated serum levels of neopterin and soluble interleukin-2 receptor in patients with ovarian cancer. Gynecol Oncol, 1994, 52(3): 386-386

[5] PavlidisN A, BairaktariE, Kalef-EzraJ, et al. . Serum soluble interleukin 2 receptors in epithelial ovarian cancer patients. Int J Biol Markers, 1995, 10(2): 75-75

[6] ChrobakL. Clinical significance of soluble interleukin-2 receptor. Acta Medica, 1996, 39(1): 3-3